Svb Financial Group Stock News

Here's how the 50 best-performers in the S&P 500 fared, plus what Wall Street analysts think will happen this year.

Smart Beta ETF report for RYF

FHB vs. SIVB: Which Stock Is the Better Value Option?

Shares of SVB Financial Group (NASDAQ:SIVB) have received an average recommendation of “Buy” from the nineteen brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company. The average […]

A fresh report by @SVB_Financial explores the current state of the fintech landscape including a view into investments by geography, fintech sectors, exits and revenue as well as a spotlight on payment facilitation. #AYearInFintech #Report The post Analysis of Silicon Valley Banks State of Fintech 2021 Report appeared first on The Fintech Times .

Pfizer, Inc. (NYSE: PFE ) announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration. The Pfizer Analysts: SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer. BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target. Broad Label, Increased Supply To Give Pfizer Dominant Market Position: Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc. (NYSE: MRK ), which submitted its application for its molnupiravir more than a month ahead of Pfizer, Porges said in a note. The analyst sees the increase in Pfizer''s expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink''s current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said. Revenue contribution will drop to $10 billion in 2024, the analyst said.

Bank of Montreal (BMO) enters an agreement to acquire BNP Paribas' U.S. banking unit, Bank of the West.

Ninety One UK Ltd lowered its stake in shares of SVB Financial Group (NASDAQ:SIVB) by 20.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 369,432 shares of the bank’s stock after selling 95,605 shares during the period. Ninety One UK […]

SEATTLE and VANCOUVER, British Columbia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into a $25 million debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P. ("SVB"). The proceeds and funds available under the debt agreement are expected to fund the completion of the cytisinicline smoking cessation clinical development program. As part of the contingent convertible debt agreement, SVB will fund $15 million in the form of convertible indebtedness to Achieve at closing on December 22, 2021. Subject to the terms and conditions of the debt agreement and upon Achieve''s and SVB''s mutual consent (including each Lender''s receipt of all necessary internal and credit approvals), Achieve may borrow additional non-convertible term loans in an aggregate original principal amount of up to $10 million. "We are pleased to have entered into a financing agreement with Silicon Valley Bank," said John Bencich, Chief Executive Officer of Achieve Life Sciences.

Texas Permanent School Fund raised its stake in SVB Financial Group (NASDAQ:SIVB) by 0.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 9,065 shares of the banks stock after buying an additional 42 shares during the quarter. Texas Permanent School Funds holdings in SVB Financial Group were worth $5,864,000 as of its most []

180 Wealth Advisors LLC boosted its position in shares of SVB Financial Group (NASDAQ:SIVB) by 38.7% during the third quarter, Holdings Channel.com reports. The fund owned 1,033 shares of the banks stock after acquiring an additional 288 shares during the quarter. 180 Wealth Advisors LLCs holdings in SVB Financial Group were worth $713,000 as of []

Livforsakringsbolaget Skandia Omsesidigt reduced its position in SVB Financial Group (NASDAQ:SIVB) by 25.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 600 shares of the banks stock after selling 200 shares during the period. Livforsakringsbolaget Skandia Omsesidigts holdings in SVB Financial Group were worth $388,000 at the end of the most recent []

Equillium, Inc. (NASDAQ:EQ) Stock analysts at SVB Leerink boosted their FY2021 earnings estimates for Equillium in a research note issued on Monday, December 13th. SVB Leerink analyst T. Smith now expects that the company will post earnings per share of ($1.37) for the year, up from their previous estimate of ($1.40). SVB Leerink currently []

The Zacks Analyst Blog Highlights: SVB Financial, East West Bancorp and BOK Financial